Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model.

The purpose of this study was to prepare dexamethasone-loaded polymeric nanoparticles and evaluate their potential for transport across human placenta. Statistical modeling and factorial design was applied to investigate the influence of process parameters on the following nanoparticle characteristics: particle size, polydispersity index, zeta potential, and drug encapsulation efficiency. Dexamethasone and nanoparticle transport was subsequently investigated using the BeWo b30 cell line, an in vitro model of human placental trophoblast cells, which represent the rate-limiting barrier for maternal-fetal transfer. Encapsulation efficiency and drug transport were determined using a validated high performance liquid chromatography method. Nanoparticle morphology and drug encapsulation were further characterized by cryo-transmission electron microscopy and X-ray diffraction, respectively. Nanoparticles prepared from poly(lactic-co-glycolic acid) were spherical, with particle sizes ranging from 140 to 298 nm, and encapsulation efficiency ranging from 52 to 89%. Nanoencapsulation enhanced the apparent permeability of dexamethasone from the maternal compartment to the fetal compartment more than 10-fold in this model. Particle size was shown to be inversely correlated with drug and nanoparticle permeability, as confirmed with fluorescently labeled nanoparticles. These results highlight the feasibility of designing nanoparticles capable of delivering medication to the fetus, in particular, potential dexamethasone therapy for the prenatal treatment of congenital adrenal hyperplasia.

[1]  Claudia J. Bode,et al.  In vitro models for studying trophoblast transcellular transport. , 2006, Methods in molecular medicine.

[2]  Xiaoying Wang,et al.  Preparation of nanoparticles by solvent displacement for drug delivery: a shift in the "ouzo region" upon drug loading. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  Ziyaur Rahman,et al.  Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. , 2010, International journal of pharmaceutics.

[4]  Michael J. Campolongo,et al.  Drug delivery: Old polymer learns new tracts. , 2009, Nature materials.

[5]  Zhirong Zhang,et al.  Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles , 2007, Archives of pharmacal research.

[6]  Elias Fattal,et al.  Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. , 2007, International journal of pharmaceutics.

[7]  David C. Martin,et al.  Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. , 2006, Biomaterials.

[8]  Yasuo Yoshioka,et al.  Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. , 2011, Nature nanotechnology.

[9]  Karsten Mäder,et al.  Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[10]  M. New,et al.  Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. , 2011, Pediatric clinics of North America.

[11]  Steven J Siegel,et al.  Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. , 2008, International journal of pharmaceutics.

[12]  P. Sylvester,et al.  Preparation and in vitro antiproliferative effect of tocotrienol loaded lipid nanoparticles , 2010 .

[13]  M. Ferrari,et al.  Size of the nanovectors determines the transplacental passage in pregnancy: study in rats. , 2011, American journal of obstetrics and gynecology.

[14]  S. Weaver,et al.  Structure of the Recombinant Alphavirus Western Equine Encephalitis Virus Revealed by Cryoelectron Microscopy , 2010, Journal of Virology.

[15]  H. Fessi,et al.  Physicochemical Parameters Associated with Nanoparticle Formation in the Salting-Out, Emulsification-Diffusion, and Nanoprecipitation Methods , 2004, Pharmaceutical Research.

[16]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[17]  Robert Langer,et al.  PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. , 2009, Biomaterials.

[18]  W. Mark Saltzman,et al.  Nanotechnology for delivery of drugs to the brain for epilepsy , 2009, Neurotherapeutics.

[19]  Hanne Mørck Nielsen,et al.  High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  M. New An Update of Congenital Adrenal Hyperplasia , 2004, Annals of the New York Academy of Sciences.

[21]  Michael Tseng,et al.  Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  H. Okada,et al.  Controlled Release of LHRH Agonist, Leuprolide Acetate, from Microcapsules: Serum Drug Level Profiles and Pharmacological Effects in Animals , 1989, The Journal of pharmacy and pharmacology.

[23]  Jayanth Panyam,et al.  Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. , 2004, Journal of pharmaceutical sciences.

[24]  F P Booy,et al.  Electron microscopy of frozen biological suspensions , 1983, Journal of microscopy.

[25]  C. Weiner,et al.  9a Medical fetal therapy , 1995 .

[26]  J. Rinehart,et al.  Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants: Optimization and In Vitro Characterization , 2008, The AAPS Journal.

[27]  S. Nimkarn,et al.  Congenital adrenal hyperplasia due to 21‐hydroxylase deficiency , 2010, Annals of the New York Academy of Sciences.

[28]  H. M. Nielsen,et al.  In vitro placental model optimization for nanoparticle transport studies , 2012, International journal of nanomedicine.

[29]  K. Audus,et al.  Transport and metabolism of opioid peptides across BeWo cells, an in vitro model of the placental barrier. , 2002, International journal of pharmaceutics.

[30]  S. Schwendeman,et al.  Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Claus-Michael Lehr,et al.  Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[33]  J. Kreuter Drug targeting with nanoparticles , 1994, European Journal of Drug Metabolism and Pharmacokinetics.

[34]  H. Okada,et al.  One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. , 1997, Advanced drug delivery reviews.

[35]  J. Zelikoff,et al.  Cadmium associated with inhaled cadmium oxide nanoparticles impacts fetal and neonatal development and growth. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  H. Bruinse,et al.  Congenital Adrenal Hyperplasia: Do the Benefits of Prenatal Treatment Defeat the Risks? , 2010, Obstetrical & gynecological survey.

[37]  Jesper B Nielsen,et al.  Placental transport and in vitro effects of Bisphenol A. , 2010, Reproductive toxicology.

[38]  P. Myllynen,et al.  Kinetics of gold nanoparticles in the human placenta. , 2008, Reproductive toxicology.

[39]  E. Ritzén Prenatal dexamethasone treatment of fetuses at risk for congenital adrenal hyperplasia: benefits and concerns. , 2001, Seminars in neonatology : SN.

[40]  M. New,et al.  Prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency , 2009, Molecular and Cellular Endocrinology.

[41]  R. Kannan,et al.  Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[42]  M. New,et al.  EXTENSIVE PERSONAL EXPERIENCE: Prenatal Diagnosis for Congenital Adrenal Hyperplasia in 532 Pregnancies , 2001 .

[43]  Dae-Duk Kim,et al.  Enhancing effect of surfactants on fexofenadine.HCl transport across the human nasal epithelial cell monolayer. , 2007, International journal of pharmaceutics.

[44]  A. Welle,et al.  PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[45]  Xiangrong Song,et al.  Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[46]  Peter Wick,et al.  Barrier Capacity of Human Placenta for Nanosized Materials , 2009, Environmental health perspectives.

[47]  Xiangrong Song,et al.  PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. , 2008, International journal of pharmaceutics.

[48]  V. Montori,et al.  Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21‐hydroxylase (CYP21A2) deficiency: a systematic review and meta‐analyses , 2010, Clinical endocrinology.

[49]  A. Ludwig,et al.  Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. , 2006, International journal of pharmaceutics.

[50]  N. Zhang,et al.  Studies on bioadhesive PLGA nanoparticles: A promising gene delivery system for efficient gene therapy to lung cancer. , 2009, International journal of pharmaceutics.

[51]  L. Knudsen,et al.  Modeling placental transport: correlation of in vitro BeWo cell permeability and ex vivo human placental perfusion. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[52]  R. A. Jain,et al.  The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. , 2000, Biomaterials.

[53]  K. Audus,et al.  Low-affinity uptake of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (4-Di-1-ASP) in BeWo cells. , 2007, Biochemical pharmacology.